1. Purpose & Scope

This Editorial Policy governs all health, pharmaceutical, and clinical content published on sunnypharma.info. It applies to product information pages, condition guides, FAQ sections, news articles, blog posts, patient resources, and any other written or multimedia content accessible to the public.

This policy exists to:

• Ensure every piece of content is medically accurate and evidence-based.
• Protect patients from misinformation about medications, dosing, and safety.
• Build and maintain the trust of patients, caregivers, and healthcare providers.
• Comply with applicable pharmaceutical advertising and health communication regulations in the United States and Canada.
• Signal to search engines and third-party evaluators that Sunny Pharma® meets the highest standards of Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T).

2. Editorial Independence

Sunny Pharma®’s editorial content is produced independently of commercial interests. While we are a pharmacy service and derive revenue from medication sales, commercial relationships have no bearing on the clinical accuracy or editorial tone of any content we publish.

2.1 Separation of Content and Commerce

Editorial content is created and reviewed by qualified medical and pharmaceutical professionals. No product manufacturer, supplier, or commercial partner may direct, alter, or withhold editorial content. Sponsored or partner content — if ever published — will be clearly and prominently labeled as such and will be held to the same medical accuracy standards as original editorial content.

2.2 No Editorial Conflicts of Interest

All contributors, reviewers, and editors are required to disclose any financial, professional, or personal relationships that could constitute a conflict of interest with respect to the content they are authoring or reviewing. Undisclosed conflicts of interest are grounds for removal of content and disqualification from the editorial process.

3. Content Creation Standards

3.1 Evidence Hierarchy

All clinical claims made on sunnypharma.info must be supported by credible evidence. We follow a strict evidence hierarchy when sourcing information:

3.2 Writing Standards

All content must adhere to the following writing standards:

• Plain language at an accessible reading level (target: U.S. Grade 8–10), without sacrificing clinical accuracy.
• Empathetic, non-stigmatizing language — particularly for HIV and Hepatitis C content, in alignment with UNAIDS and CDC communication guidelines.
• Accurate use of brand names, generic names (INN), and drug class terminology.
• Dosing information presented only in conjunction with a clear recommendation to consult a licensed prescriber.
• No absolute or guaranteeing language regarding treatment outcomes (e.g., will cure, guaranteed results).
• Claims about medication cost or savings must be accurate, time-stamped, and regularly verified.

3.3 Use of Artificial Intelligence (AI)

Sunny Pharma® may use AI language tools to support content drafting, research summarization, and readability optimization. However, all AI-assisted content is subject to the same full editorial and medical review process as human-authored content. AI is a productivity tool, not an editorial authority. No AI-generated content is published without expert human review and approval. We are transparent about this policy.

4. Medical Review Process

All health, clinical, and pharmaceutical content published on sunnypharma.info undergoes a structured medical review process before publication. This process is modeled on best practices established by leading health platforms including Healthline Media, WebMD, and Medscape.

4.1 Reviewer Credentials

Medical reviewers on the Sunny Pharma® network must hold current, valid licensure in their specialty jurisdiction. Accepted credentials include:

• M.D. or D.O. with active board certification in a relevant specialty
• Pharm.D. with clinical pharmacy practice experience
• R.Ph. (Registered Pharmacist) with relevant specialty experience
• N.P. or P.A. with relevant clinical specialty in an advisory or supporting review role

All reviewer credentials are verified prior to engagement. Reviewer names and credentials are displayed on applicable content pages in accordance with Google’s E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness) standards.

4.2 Reviewer Disclosure

Each piece of reviewed content will display a byline that includes the reviewer’s name, professional credentials, specialty, and the date of medical review. Reviewers must disclose any financial relationships with pharmaceutical manufacturers relevant to the content being reviewed.

5. Content Categories & Specific Standards

5.1 HIV Treatment Content

Content covering HIV antiretroviral therapy (ART) — including medications such as Biktarvy, Descovy, Tivicay, Triumeq, Truvada, Reyataz, and Prezista — must:

• Accurately represent indication (treatment vs. PrEP) without conflating the two.
• Reference current DHHS Adult and Adolescent ARV Treatment Guidelines as the primary clinical framework.
• Use person-first, destigmatizing language consistent with CDC and UNAIDS recommendations.
• Clearly note the requirement for a valid prescription and ongoing clinical monitoring.
• Not make therapeutic equivalence claims between branded and generic formulations without regulatory citation.

5.2 Hepatitis C Treatment Content

Hepatitis C treatment content must reference current AASLD/IDSA HCV Guidance as the authoritative clinical standard, correctly distinguish between genotype-specific and pangenotypic regimens, and accurately represent cure rates (SVR12) from clinical trial data only — no extrapolation without citation.

5.3 Weight Loss Medication Content

Content covering weight management medications must comply with FTC guidelines on health claims, accurately represent FDA-approved indications and contraindications, not imply results beyond those demonstrated in controlled clinical trials, and always include a recommendation to consult a physician before initiating treatment.

5.4 Pricing & Cost Information

All pricing information must be clearly dated, accompanied by a disclaimer that prices are subject to change, and verified for accuracy on a minimum quarterly basis. Comparative pricing claims must use current, verifiable reference prices.

6. Sourcing & Citation Standards

Sunny Pharma® follows strict sourcing standards aligned with those of leading health publishers. All factual and clinical claims in published content must be supported by in-text citations linked to primary or secondary sources.

• All citations must link directly to the source document (e.g., PubMed abstract, FDA label page, official guideline PDF).
• Sources must be dated within the last five years for clinical content, unless referencing foundational pharmacology or mechanism-of-action data.
• No citations to secondary aggregators (e.g., Wikipedia, About.com) as sole sources for clinical claims.
• A minimum of three credible sources is required for any standalone clinical article.
• Patient-facing content cites sources in an accessible format with links; clinical-facing content follows AMA citation style.

7. Content Updates, Corrections & Retractions

Medical information evolves. Sunny Pharma® is committed to keeping content current and correcting errors promptly and transparently.

7.1 Regular Content Reviews

7.2 Corrections Policy

If factual errors are identified in published content — whether discovered internally or reported by readers — Sunny Pharma® will: (1) investigate within 48 hours, (2) publish a transparent correction notice at the top of the affected page, (3) update all relevant citations, and (4) document the correction in our internal Content Audit Log. We do not silently edit content to conceal errors. Readers are encouraged to report inaccuracies via our Contact page.

7.3 Content Dating & Transparency

Every piece of health and clinical content on sunnypharma.info will display three dates: (1) Original publication date, (2) Medical review date, and (3) Last updated date. This transparency allows readers and search evaluators to assess the currency of information at a glance.

8. Legal & Regulatory Compliance

Sunny Pharma® operates as a Patient Access Partner and all content is designed to comply with applicable regulations in both the United States and Canada.

• Content does not constitute medical advice, diagnosis, or treatment. Every clinical page includes a standardized disclaimer directing patients to consult their prescribing physician or pharmacist.
• Prescription drug information conforms to FDA-approved labeling. Off-label use information, where published, is clearly identified as such and supported by peer-reviewed evidence.
• Pharmaceutical advertising content (if any) complies with FDA regulations for direct-to-consumer drug advertising (21 CFR Part 202) and Health Canada’s equivalent standards.
• Content pertaining to PrEP medications (e.g., Truvada, Descovy) complies with CDC communication standards and avoids stigmatizing language.
• All patient privacy considerations are addressed under our Privacy Policy in accordance with HIPAA and PIPEDA.

9. Audience Considerations

Sunny Pharma® content serves a dual audience: patients and caregivers seeking medication information and cost savings, and healthcare providers seeking clinical reference material. Content is clearly differentiated by audience where applicable.

• Patient-facing content uses accessible language and focuses on real-world utility: cost, access, side effect management, and adherence.
• Clinical reference content uses appropriate medical terminology and links directly to primary literature.
• All content maintains sensitivity to the unique emotional and social dimensions of HIV, Hepatitis C, and weight management — conditions often accompanied by stigma, anxiety, and complex socioeconomic factors.

10. Reader Feedback & Community Standards

Sunny Pharma® values reader feedback as a critical quality signal. We maintain an active feedback mechanism for content accuracy reports. Submitted feedback is reviewed by our editorial team within five business days. Readers who identify an error or outdated reference are encouraged to contact us directly at sunnypharma.info.

Any user-generated content (comments, reviews) published on the site must adhere to our Community Guidelines: no medical advice to third parties, no stigmatizing language, and no promotion of unapproved or counterfeit medications. Violations will result in content removal.

11. SEO & Content Integrity

Sunny Pharma® is committed to achieving high search engine visibility through the merit of its content quality — not through manipulation. Our SEO practices fully align with Google’s Search Essentials and the principles of Helpful Content.

• Content is written for patients and healthcare consumers first — not search engines.
• We do not engage in keyword stuffing, cloaking, hidden text, or any other deceptive SEO practice.
• All structured data (schema markup) accurately reflects page content and follows Schema.org standards for MedicalWebPage, Drug, and FAQPage types.
• Internal linking is editorially relevant and serves the reader’s informational journey.
• We actively seek to earn backlinks from authoritative health and medical institutions through content merit.
• Content length and structure are determined by the informational needs of the reader, not arbitrary keyword density targets.

12. Policy Governance & Review

This Editorial Policy is owned by the Sunny Pharma® Editorial Director and reviewed annually, or sooner in the event of significant regulatory changes, search engine algorithm updates with editorial implications, or substantive changes to the clinical guidelines governing our key therapeutic areas.

All staff, contractors, and third-party contributors involved in content creation or review for sunnypharma.info must acknowledge and agree to this policy prior to engagement.

Questions regarding this policy should be directed to the Sunny Pharma® editorial team via the Contact page at sunnypharma.info.